Compare Old Dominion Freight Line Inc (ODFL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Old Dominion Freight Line Inc trades at $184.8 (market cap $37.98B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Old Dominion Freight Line Inc is far larger — about 5.2× Spyre Therapeutics Inc. Common Stock's market cap, and Old Dominion Freight Line Inc pays a 0.63% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 77 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ODFL | SYRE | |
|---|---|---|
Market Cap | $37.98B | $7.35B |
Volume | 1,713,056 | 1,624,631 |
Sector | Industrials | Health |
52-Week High | $248.73 | $108.92 |
52-Week Low | $126.29 | $22.18 |
Typical Hold Time | 77 Days | 0 Days |
Enterprise Value | $37.72B | $6.35B |
Dividend Yield | 0.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $184.37, up 1.35% today, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.68 exceeding the $1.54 estimate. Revenue for 2025 was $5.50B, with a net income margin of 19.44%. A 4.9% general rate increase effective October 5, 2026, aims to offset rising costs and support network investments.
ODFL presents a mixed outlook: robust profitability and analyst consensus target of $230.93 suggest upside, but high valuation multiples (P/E 35.23) and bearish technicals indicate near-term pressure. Key risks include freight demand volatility and competitive pressures, while institutional buying and earnings momentum support long-term growth potential.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
